Overview
TARA market data
Price History
TARA price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.34 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.51 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.97 – $7.82 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $214.1 · P/B 1.40.
Company News
8-K filing — Protara Therapeutics, Inc. (TARA)SEC EDGAR · Jun 29, 2026, 9:02 PM
Protara Therapeutics Enters $100M At-the-Market Equity Sales Agreement With TD CowenBenzinga · May 28, 2026, 9:20 PM
Oppenheimer Maintains Outperform on Protara Therapeutics, Raises Price Target to $28Benzinga · May 20, 2026, 4:10 PM
Protara Therapeutics To Host Investor Webinar On TARA-002 Program And Treatment Landscape For Lymphatic Malformations On May 19, 2026Benzinga · May 18, 2026, 12:15 PM
Protara Therapeutics Reports 55% Complete Response Rate In Bladder Cancer StudyBenzinga · May 15, 2026, 3:40 PM
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBCGlobenewswire Inc · May 15, 2026, 11:15 AM
Protara Therapeutics Reports TARA-002 Achieves 72% Complete Response Rate In BCG-Naïve NMIBC Patients With Durable 55% Rate At 12 MonthsBenzinga · May 15, 2026, 11:10 AM
JP Morgan Maintains Overweight on Protara Therapeutics, Lowers Price Target to $26Benzinga · May 14, 2026, 6:19 PM
Protara Therapeutics May Offer Up To $300M Of SecuritiesBenzinga · May 14, 2026, 10:06 AM
Protara Therapeutics Q1 EPS $(0.31) Beats $(0.37) EstimateBenzinga · May 13, 2026, 12:07 PM